ATG4B and acute myeloid leukemia: Inhibition of ATG4B enhanced PRMT1‐mediated DNA damage responses, suppressed cell proliferation, reduced the mutation burden, and prolonged survival in mice with MLLT3‐KMT2A‐induced AML and in those bearing AML patient‐derived xenografts.